EPIDEMIOLOGIC SOLUTIONS CORPORATION (EIN 852306010) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2020

Legal Domicile

Principal Officer

RONNIE GODEAUX OFFICER

Tax Period

2023-01-01 to 2023-12-31

EPIDEMIOLOGIC SOLUTIONS CORPORATION, founded in 2020, is a micro nonprofit in the Medical Research sector that reported $22K in total revenue in fiscal year 2023. Revenue fell 98% from the prior year — a significant decline worth monitoring. Expenses of $469K exceeded revenue, resulting in a 2010% operating deficit.

Mission

MOST SIGNIFICANTLY, RESEARCH TO DEVELOP TREATMENTS FOR A RANGE OF DISEASES, PRINCIPALLY FOCUSED ON EXTRACORPOREAL METHOD TREATSBLOOD-BORNE,NEUROLOGIC AND INFECTIOUS DISEASES, BY REMOVING BODILY FLUIDS IN A CONTINUOUS FASHION LIKE DIALYSIS, OR IN A BATCH PROCESS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $1,148,591

Program Service Revenue $0

Investment Income $0

Other Revenue $-1,126,357

TOTAL REVENUE $22,234

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $458,868

Other Expenses $469,188

TOTAL EXPENSES $469,188

Year-over-Year Comparison

	2023	2022	Change
Revenue	$22,234	$940,634	-1.0%
Expenses	$469,188	$336,927	+0.4%
Net Income	$-446,954	$603,707	-1.7%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

N/A

Independent Members

N/A

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RONNIE GODEAUX	CEO	0.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$22,234	$469,188	$574,186	$-446,954
2022	$940,634	$336,927	$997,115	$603,707
2021	$-499,806	No data	$393,408	No data
2020	$893,214	No data	$893,214	No data

EPIDEMIOLOGIC SOLUTIONS CORPORATION